Claims
- 1. Use of estrogen receptor (ER)β-selective agonists for the production of a pharmaceutical agent for triggering somatotropic and/or organotropic effects in the CNS, the circulatory system, the skeletal system and/or the immune system in the aging male and female organism (anticatabolic therapy).
- 2. Use according to claim 1 for stimulation of the growth hormone.
- 3. Use according to claim 1 for stimulation of IGF-I.
- 4. Use according to claim 1 for influencing (increasing) the growth of muscle mass.
- 5. Use according to claim 1 for preserving muscle mass.
- 6. Use according to claim 1 for influencing (increasing) the growth of bone mass.
- 7. Use according to claim 1 for preserving bone mass.
- 8. Use according to claim 1 for influencing the growth of the thymus.
- 9. Use according to claim 1 for preserving the thymus and its function.
- 10. Use according to claim 1 for increasing the IGF-I level.
- 11. Use according to claim 1 for stimulation of the adrenal secretion of androgenic hormones (DHEA, DHEA-S, androstenedione).
- 12. Use according to claim 1 for stimulation of testicular hormone secretion (testosterone).
- 13. Use according to claim 1 for increasing the level of HDL-cholesterol.
- 14. Use according to claim 1 for improving the state of nutrition.
- 15. Use of an estrogen receptor (ER)β-selective agonist according to claim 1 in a dosage of 10 μg to 10 mg daily absolute.
- 16. Use of 8β-vinyl-1,3,10-estratriene-3,17β-diol according to claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
101 51363.1 |
Oct 2001 |
DE |
|
Parent Case Info
[0001] This application claims the benefit of the filing date of U.S. Provisional Application Serial No. 60/331,529 filed Nov. 19, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60331529 |
Nov 2001 |
US |